updated 12/31/2008 11:02:04 AM ET 2008-12-31T16:02:04

The Food and Drug Administration is still reviewing King Pharmaceuticals Inc.'s pain drug candidate Embeda, King said Wednesday.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

An FDA ruling on Embeda, a morphine pill that is designed to be abuse-resistant, was due Tuesday. King said it is in discussions with the agency and suggested the review will last through early 2009.

Embeda capsules contain an extended-release dose of morphine and a core of naltrexone, a drug that is used to combat addiction. King said that if the pill is crushed or chewed, rather than swallowed as intended, the naltrexone will be released, canceling out the high of the morphine.

Pain pills are often abused by users who grind them up to snort or inject.

In November, an FDA panel said Embeda might help deter abuse, but indicated it was not a major improvement on older drugs. The panel also said there were potential safety issues with exposing patients to naltrexone.

The drug was developed by Alpharma Inc. King completed its $1.6 billion buyout of Alpharma Tuesday, adding Embeda to its pipeline. The company is also developing an abuse-resistant opioid drug called Remoxy.

Remoxy contains oxycodone in a viscuous form, which is designed to frustrate attempts defeat to its time-release formula by crushing, snorting or dissolving the drug in alcohol.

Oxycodone is marketed by Purdue Pharma as OxyContin.

King Pharmaceuticals shares fell 2 cents to $10.39 in morning trading.

Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments